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We investigated the safety and efficacy of a methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) combination regimen as
second-line chemotherapy for patients with advanced or metastatic transitional cell carcinoma who failed first-line gemcitabine and
cisplatin (GC) chemotherapy. Thirty patients who had progressed or relapsed after GC chemotherapy as first-line treatment were
enrolled in this study. The major toxicities were neutropaenia and thrombocytopaenia. A grade 3 or 4 neutropaenia occurred in 19
(63.3%) and a grade 3 or 4 thrombocytopaenia developed in nine patients (30.0%). There were no life-threatening complications
during the study. The overall response was 30%. A complete response was achieved in two patients (6.7%) and a partial response in
seven (23.3%). The overall disease control rate was 50%. Seven out of 16 patients who had responded previously to GC responded
to M-VAC, while 2 out of 14 who had not responded to GC responded to M-VAC. The median response duration was 3.9 months
and the median progression-free survival was 5.3 months. The median overall survival was 10.9 months. M-VAC showed encouraging
efficacy and reversible toxicities in patients who had progressed after GC chemotherapy and, especially, M-VAC appears to be a
reasonable option as a sequential treatment regimen in patients who responded previously to GC chemotherapy.
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Urothelial carcinoma is the second most common genitourinary
malignancy. Since advanced urothelial carcinoma is sensitive to
chemotherapeutic agents, systemic combination chemotherapy has
been the standard treatment that can result in long-term survival
in some patients with advanced or metastatic transitional cell
carcinoma. The most commonly used regimens are the metho-
trexate, vinblastine, doxorubicin and cisplatin (M-VAC) combina-
tion or the gemcitabine and cisplatin (GC) combination regimen
(Bamias et al, 2006; Garcia and Dreicer, 2006; Pectasides et al,
2007). The M-VAC regimen was introduced at the Memorial Sloan-
Kettering hospital in the mid-1980s and it improved overall
survival to a median slightly in excess of 12 months (Sternberg
et al, 1988; Culine, 2002). Thereafter, a GC regimen was developed
and, when it was compared with M-VAC, it showed comparable
efficacy with reduced side effects (Moore et al, 1999; von der Maase
et al, 1999, 2000; Kaufman et al, 2000). Recently published long-
term results confirmed a similar 5-year survival and progression-
free survival rates for GC and M-VAC (von der Maase et al, 2005).
On the basis of these results, M-VAC or GC has become the
standard first-line treatment for patients with advanced transi-
tional cell carcinoma.
However, a dismal prognosis is predicted in patients whose
disease progresses after first-line chemotherapy. Therefore, safe
and effective second-line chemotherapy regimens are needed for
patients who have a disease relapse after initial chemotherapy
treatment. Currently, there is limited information on additional
treatment of patients who fail first-line platinum-based chemo-
therapy. Taxanes, gemcitabine and ifosfamide have shown
promising results after failure of first-line chemotherapy (Tu
et al, 1995; McCaffrey et al, 1997; Witte et al, 1997; Sweeney et al,
1999; Krege et al, 2001; Meluch et al, 2001; Sternberg et al, 2001;
Bellmunt et al, 2002; Vaughn et al, 2002). However, the response
rates to these regimens have been variable and durable remissions
have been limited.
Although GC is widely considered as the new standard for first-
line treatment in patients with advanced bladder cancer, in several
countries, there is no data on salvage chemotherapy after failure of
GC. Moreover, the role of M-VAC as second-line treatment after
failure of GC is unknown. We therefore investigated the safety and
efficacy of the M-VAC regimen as salvage chemotherapy for the
patients in whom first-line GC chemotherapy failed.
PATIENTS AND METHODS
Patient eligibility
Patients with histologically confirmed advanced or metastatic
transitional cell carcinoma were eligible to participate in this
study. All patients had evidence of disease progression or relapse
after GC chemotherapy as first-line treatment. For GC chemotherapy,
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sgemcitabine was given at a dose of 1000mgm
 2 on days 1, 8 and
15, and cisplatin was given at a dose of 70mgm
 2 on day 2.
Adequate organ function was required and an Eastern Cooperative
Oncology Group performance status of 0–2, an absolute
granulocyte count X1500mm
 3, platelet count X100000mm
 3,
serum creatinine p1.5mgdl
 1, creatinine clearance X50mlmin
 1
and a serum bilirubin p2mgdl
 1 were required for the treatment.
The exclusion criteria included the presence of brain metastases or
persistent toxicity from previous GC chemotherapy. Informed
consent was obtained before entry into the study. The study was
conducted in accordance with the Declaration of Helsinki Principle
and Good Clinical Practice and was approved by an independent
ethics committee.
Treatment schedule
The patients received methotrexate 30mgm
 2 on days 1, 15 and
22; vinblastine 3mgm
 2 on days 2, 15 and 22; doxorubicin
30mgm
 2 on day 2; and cisplatin 70mgm
 2 on day 2. The cycles
were repeated every 28 days. The patient response was evaluated
every three cycles. An additional three cycles with same regimen
were provided to patients with no progression at the response
evaluation. A third-line chemotherapy regimen was initiated in
patients who had progressed if the patients had a good
performance status and adequate organ function.
Response and toxicity assessment
All patients were evaluated for their response to treatment after
completing three cycles except for those cases with symptomatic
progression. Early evaluations were performed in patients with
clinical evidence of progressive disease (PD). Patient response was
evaluated according to the Response Evaluation Criteria in Solid
Tumors (Therasse et al, 2000). A complete response (CR) was
defined as the disappearance of all clinical and radiological signs of
target lesions. A partial response (PR) was a X30% decrease in the
overall sum of the diameter of the target lesions; a PD was a X20%
increase in the overall sum of the diameter of the target lesions;
and stable disease was neither a sufficient shrinkage to qualify
for PR nor sufficient increase to qualify for PD. In cases with a PR
or CR, a second assessment 4 weeks later was required for
confirmation of the response. The toxicity was graded according to
the National Cancer Institute’s common toxicity criteria version
2.0. Patients who received at least one dose of M-VAC were
assessed for toxicity.
Statistical considerations
The duration of response was defined as the time from the first
objective status assessment of response to the initial date of a
documented progression. The progression-free survival was
defined as the time from study entry to the initial date of evidence
of progression, death or loss to follow-up. The progression-free
survival of patients alive without progression was recorded at the
time of the last follow-up evaluation. The overall survival was
defined as the interval between the date of study entry to death or
the last follow-up evaluation. The progression-free survival and the
overall survival were estimated using the Kaplan–Meier method.
The analyses were performed using 5% as the level of significance.
RESULTS
Patient characteristics
Between May 2002 and December 2006, 30 patients were enrolled
in this study. The baseline characteristics of the patients are shown
in Table 1. The median age was 64 years (range, 38–79). There
were 24 men and 6 women. Fourteen patients had primary
tumours. Nineteen patients had visceral metastases and 11 patients
had regional lymph-node metastases only.
For first-line GC chemotherapy, the median number of cycles
was five (range, 2–9) and the response rate was 53.3%. There were
no interrupted schedules or dose adjustments due to persistent
toxicities. All patients received at least three cycles of GC except for
one patient. In one patient, GC chemotherapy was discontinued
during a second cycle because acute renal failure developed due to
progression of pelvic lymph node metastases.
After disease progression or relapse was confirmed, the patients
received the M-VAC regimen. The median treatment-free interval
between GC and M-VAC was 2.5 months (range, 0.5–20.4) and
the median number of cycles for the M-VAC regimen was three
(range, 1–12).
Toxicity
All enrolled patients were evaluated for toxicity (Table 2). The
treatment was generally well-tolerated. The major haematological
toxicities were neutropaenia and thrombocytopaenia. A grade 3 or
4 neutropaenia occurred in 19 patients (63.3%); they received
granulocyte colony-stimulating factor until their neutrophil counts
were restored. A grade 3 or 4 thrombocytopaenia developed in
nine patients (30.0%); there was no haemorrhagic event due to
the thrombocytopaenia. Grade 3 or 4 anaemia developed less
frequently and was identified in five patients (16.7%). The major
nonhaematologic toxicities were alopecia and mucositis. Grade 2
alopecia developed in 14 patients (46.7%) and grade 3 or 4
mucositis in four (13.3%); most nonhaematologic toxicities were
confined to grade 1 or 2 (Table 2). All toxicities were reversible and
no life-threatening complications were observed during the study.
Omission of methotrexate and vinblastine on day 15 and/or 22
or delay of a subsequent cycle occurred in cases with persistent
severe haematological toxicities despite appropriate management.
Methotrexate and vinblastine on day 15 or 22 were omitted in 23
patients. The median for an omitted scheduled cycle was one per
patient (range, 0–16). The schedules on day 15 or 22 were delayed
in 11 patients. The median number of delayed schedules was zero
Table 1 Characteristics of the study population
Characteristics No. of patients
Total enrolled patients 30
Age
Median (years) 64
Range (years) 38–79
Gender
Males 24
Females 6
ECOG performance status
01 6
11 1
23
Disease extents
Visceral metastases 19
Regional lymph-node metastases only 11
Sites of diseases
Primary 14
Local recurrence 3
Lymph nodes 22
Lung 7
Liver 4
Bone 5
Others 2
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s(range, 0–3); all patients could receive scheduled treatments after
1 week. A subsequent cycle was delayed for 1 week in one patient.
Response rates and survival
The response to treatment was assessed in all registered patients.
The overall response rate was 30%. A CR was achieved in two
patients (6.7%) and a PR in seven (23.3%). Stable disease was
observed in six patients (20.0%). The overall disease control rate
was 50%. The characteristics of the responders are listed in
Table 3. Seven out of 16 patients who had responded previously to
GC responded to M-VAC, while 2 out of 14 who had not responded
to GC responded to M-VAC. A response was observed in 4 out of
11 (36.4%) patients with only lymph node metastases and in 5 out
of 19 (26.3%) patients with visceral metastases.
The median response duration was 3.9 months (95% CI: 3.7–
4.1) and the median progression-free survival was 5.3 months
(95% CI: 3.1–7.5). A majority of patients finally had disease
progression; only three patients remained with no disease
progression at the last follow-up evaluation. Twenty patients died
and 10 patients were still alive at the last follow-up. The median
overall survival was 10.9 months (95% CI: 5.5–16.3). The actuarial
1- and 2-year survival rates were 49.8 and 16.6%, respectively
(Figure 1).
DISCUSSION
M-VAC is the most effective regimen as first-line treatment for
transitional cell carcinoma of the urothelial tract but the role of
M-VAC as second-line chemotherapy has never been studied
although a variety of other agents have been investigated. Since GC
chemotherapy was introduced as first-line chemotherapy for
urothelial carcinoma, the role of the M-VAC regimen after GC
remains to be defined. The results from our study showed that
M-VAC chemotherapy was effective for urothelial carcinoma
progression following first-line GC chemotherapy. M-VAC appears
to be effective in patients who become less sensitive to the
synergistic effects of gemcitabine and cisplatin.
In our study, the M-VAC regimen had a response rate of 30% in
patients with disease progression after GC failure. There may be
several explanations for this result. Cisplatin is one of the most
potent chemotherapeutic agents for advanced transitional cell
carcinoma and the failure of GC treatment does not imply a
cisplatin-refractory status. Cisplatin may still be active in patients
who failed prior GC chemotherapy. In addition, patients who fail
the GC protocol may be sensitive to other potent agents such as
methotrexate, doxorubicin and vinblastine. Our favourable results
suggest that M-VAC is another option in patients with advanced
transitional cell carcinoma who failed first-line GC treatment. On
the other hand, we found a trend for a correlation between the
response to the first-line GC treatment and the response to second-
line M-VAC. Seven out of 16 patients (43.8%) who had responded
to the prior GC therapy responded to the second-line M-VAC
chemotherapy, while only 2 out of 14 (14.3%) who did not respond
to GC therapy responded to M-VAC. These findings suggest the
possibility that the response to the second-line M-VAC can be
predicted from the response to the first-line GC chemotherapy.
The difference of the response rates to second-line M-VAC
between those who responded to GC and those who did not
respond to GC treatment was not statistically significant but the
absence of significance might have been due to the small number
of patients studied. Additional trials are needed to confirm
Table 3 Characteristics of responders to second-line M-VAC regimen
No. Age Site of disease
Response
to GC
Treatment-free
interval (month)
Response
to M-VAC
RD
(month)
PFS
(month)
Current
status
Survival
(month)
1 46 Bone
Supraclavicular LN
PR 3.2 PR 6.6 8.6 Death 11.7
2 54 Retroperitoneal LN PR 4.5 PR 3.3 6.4 Death 9.2
3 66 Bladder
Lung
Retroperitoneal LN
PR 5.7 PR 3.7 7.2 Alive 9.2+
4 72 Lung
Retroperitoneal LN
PR 3 PR 3.9 7.6 Death 10.9
5 69 Pelvic recurrence
Lung
Retroperitoneal LN
PR 2 PR 3.8 7.1 Death 10.6
6 69 Bladder
Retroperitoneal LN
PD 7 CR 1.5 4.4+ Alive 5.8+
7 64 Retroperitoneal LN
Carcinomatosis
CR 1 PR 1.5 2.5+ Alive 5.3+
8 79 Retroperitoneal LN CR 10.4 CR 7.2 10.6+ Alive 11.6+
9 52 Bladder
Scrotum
PD 2.5 PR 3.9 6.7 Death 15.8
Abbreviations: CR¼complete response; LN¼lymph node; PD¼progressive disease; PFS¼progression-free survival; PR¼partial response; RD¼response duration.
Table 2 Toxicities
Grade 1 Grade 2 Grade 3 Grade 4
No. % No. % No. % No. %
Neutropaenia 1 3.3 2 6.7 6 20.0 13 43.3
Thrombocytopaenia 5 16.7 1 3.3 3 10.0 6 20.0
Anaemia 9 30.0 3 10.0 4 13.3 1 3.3
Mucositis 1 3.3 3 10.0 4 13.3 — —
Alopecia 13 43.3 14 46.7
Nausea/vomiting 14 46.7 8 26.7 — — — —
Anorexia 10 33.3 5 16.7 1 3.3 — —
Diarrhoea 2 6.7 1 3.3 — — — —
Constipation 3 10.0 1 3.3 — — —
Fatigue 5 16.7 1 3.3 — — — —
Asthenia 5 16.7 2 6.7 — — — —
Fever 3 10.0 1 3.3 — — — —
Myalgia 5 16.7 1 3.3 — — — —
Infection — — — — 1 3.3 — —
Allergic reactions 1 3.3 1 3.3 — — — —
Dizziness 1 3.3 — — — — — —
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swhether the response to first-line GC treatment can be a significant
predictor of the response to second-line M-VAC.
Most patients enrolled in this study had good renal function and
performance status. Our favourable results might have been
affected by these factors. It is reported (de Wit, 2003) that an
estimated one-third of patients with advanced urothelial carcinoma
are medically unfit for cisplatin-based chemotherapy , and in
accordance with this, in clinical practice, there is frequently a
significant deterioration of the performance status or renal
function in patients with advanced urothelial carcinoma; this is
most frequently observed in patients with first-line treatment
failure and disease progression. This makes enrolment of patients
into clinical studies or the administration of systemic chemotherapy
outside of the context of a clinical trial difficult (Bamias et al, 2006;
Garcia and Dreicer, 2006; Pectasides et al, 2007). Substitution of
new agents for cisplatin in two-drug or three-drug combinations is
required in these patients. Carboplatin can be a good alternative to
cisplatin because it is less nephrotoxic (de Wit, 2003). Phase II
trials of carboplatin, as a substitution for cisplatin in first-line
chemotherapy regimens, demonstrated that carboplatin-based
therapy was less effective than cisplatin-based therapy. However,
there is few data on carboplatin as a substitution for cisplatin-
based therapy in second-line chemotherapy (Petrioli et al, 1996;
Bellmunt et al, 1997). Randomised trials with carboplatin-based
regimens in patients who failed first-line platinum-based che-
motherapy and development of new combinations consisting of
safer and more effective agents is needed for the treatment of
patients with depleted marrow reserves and impaired renal
function after the failure of first-line chemotherapy.
Over the past 20 years, a relatively large number of agents have
been evaluated for second-line chemotherapy. The agents studied
included ifosfamide, taxanes, gemcitabine, oxaliplatin, vinflunine
and pemetrexed. However, a review of the recent literature, on
phase II trials in this population, confirms that there are very
limited options for patients who have been previously treated with
GC, M-VAC or CMV combinations (Culine et al, 2006). Taxanes
are widely used as a second-line regimen in patients with cisplatin-
refractory urothelial carcinoma. The taxanes (paclitaxel and
docetaxel) have provided objective response rates of 10–13% with
response durations of 3.0–7.4 months (McCaffrey et al, 1997;
Vaughn et al, 2002). Combinations with other agents have shown
better results. Paclitaxel combined with gemcitabine, ifosfamide,
methotrexate or cisplatin showed a 15–60% response rate and
taxanes combined with ifosfamide a 15–25% response rate (Tu
et al, 1995; McCaffrey et al, 1997; Witte et al, 1997; Sweeney et al,
1999; Krege et al, 2001; Meluch et al, 2001; Sternberg et al,
2001; Bellmunt et al, 2002; Vaughn et al, 2002). Ifosfamide showed
a 20% response rate in an ECOG study but an unacceptable
frequency of grade 3–4 CNS and renal toxicities were noted
(Witte et al, 1997). Toxicity remains the major limiting aspect of
these regimens (Roth et al, 1994; Dreicer et al, 1996; Witte et al,
1997).
Vinflunine and pemetrexed as new single agents have been
studied in phase II trials (Culine et al, 2006; Sweeney et al, 2006).
Vinflunine showed an 18% response rate and a 67% disease
control rate and pemetrexed, a new-generation antifolate, showed
a favourable therapeutic index (an overall response rate of 27.7%).
Incorporation of these new agents as second-line treatment
combination regimens is expected in future studies.
Several regimens studied as second-line chemotherapy for
urothelial carcinoma have variable response rates. This is likely
due to the variability in drug activity as well as the different patient
populations evaluated in different studies (Sweeney et al, 2006). In
most studies, the regimens used for first-line chemotherapy were
heterogeneous in a given study population (Tu et al, 1995). Most
studies on second-line chemotherapy include patients who
received M-VAC-, CMV-, GC- or taxane-based regimens, as initial
chemotherapy, or patients who did not receive any chemotherapy
(Tu et al, 1995; McCaffrey et al, 1997; Witte et al, 1997; Sweeney
et al, 1999; Krege et al, 2001; Meluch et al, 2001; Bellmunt et al,
2002; Vaughn et al, 2002; Culine et al, 2006). These confounding
factors make it difficult to interpret the true efficacy of a second-
line chemotherapy regimen. In our study, all patients received the
same regimen as first-line chemotherapy.
In conclusion, this is the first report on the efficacy and toxicity
of M-VAC as second-line chemotherapy in patients who failed
first-line GC. The main limitation of this study was the small
number of cases evaluated. M-VAC showed encouraging efficacy
and reversible toxicities in patients who had disease progression
after GC chemotherapy. Therefore, M-VAC appears to be a
reasonable option for patients who initially responded to first-
line GC chemotherapy. There are few randomised trials on second-
line chemotherapy for urothelial carcinoma; therefore, large
randomised controlled studies are required to confirm the findings
reported here.
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